Genenta Science S.p.A. (GNTA)
NASDAQ: GNTA · IEX Real-Time Price · USD
6.28
+0.33 (5.55%)
Feb 6, 2023, 10:56 AM EST - Market open
Company Description
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.
The company was incorporated in 2014 and is headquartered in Milan, Italy.
Genenta Science S.p.A.
| Country | Italy |
| Founded | 2014 |
| IPO Date | Dec 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Mr. Pierluigi Paracchi |
Contact Details
Address:
Olgettina, No. 58 Milan, L6 20132 Italy | |
| Phone | 39-02-2643-6639 |
| Website | genenta.com |
Stock Details
| Ticker Symbol | GNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $11.50 |
| CIK Code | 0001838716 |
| CUSIP Number | 36870W100 |
| ISIN Number | US36870W1009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Pierluigi Paracchi | Vice Chairman, Chief Executive Officer and GM |
| Dr. Luigi Naldini M.D., Ph.D. | Co-Founder and Chairman of the Executive Scientific Board |
| Dr. Bernard Rudolph Gentner M.D., Ph.D. | Co-Founder and Member of the Executive Scientific Board |
| Richard B. Slansky | Chief Financial Officer |
| Dr. Stefania Mazzoleni Ph.D. | Scientific Director and Communication Officer |
| Dr. Carlo Russo M.D. | Chief Medical Officer and Head of Development |
| Tim Obara | Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 1, 2023 | 6-K | Report of foreign issuer |
| Dec 22, 2022 | 6-K | Report of foreign issuer |
| Dec 15, 2022 | 6-K | Report of foreign issuer |
| Oct 25, 2022 | 6-K | Report of foreign issuer |
| Oct 25, 2022 | 6-K | Report of foreign issuer |
| Oct 3, 2022 | 6-K | Report of foreign issuer |
| Jun 14, 2022 | 6-K | Report of foreign issuer |
| May 11, 2022 | 6-K | Report of foreign issuer |
| May 2, 2022 | 20-F | Annual and transition report of foreign private issuers |
| Feb 25, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |